Oral obesity drug competition intensifies globally as Eli Lilly and Novo Nordisk seek domestic South Korean approvals, shifting the market away from injectable treatments.
Eli Lilly and Novo Nordisk are pursuing local product approvals for their respective oral therapies. This shift threatens to disrupt a market previously dominated by weekly and daily injections.
The race centers on oral glucagon-like peptide-1 receptor agonists. The expanding product pipeline gives clinicians more options for treating chronic weight management.
Eli Lilly leads part of the international momentum with its oral GLP-1 receptor agonist, orforglipron, which carries the product name Foundayo, kpanews.co.kr reported. The drug secured weight-management indication approvals in the United States, the United Arab Emirates, the United Kingdom, and China. Chinese regulators cleared the treatment as a first-class new drug under the local brand name Muyouda.
Orforglipron operates as a once-daily, non-peptide small-molecule agent. This pharmacokinetic profile removes the fasting constraints associated with other oral peptide therapies.
Clinical data supporting orforglipron demonstrate substantial reductions in total body weight over extended treatment windows. Approximately 40% of trial participants achieved a weight loss of 15% or greater from their baseline measurements.
The therapeutic impact extends beyond scale weight to specific metabolic fat distributions. Magnetic resonance evaluations in the trial cohorts indicated that visceral fat decreased by over 30%. Concurrently, waist circumferences shrank by up to approximately 11 centimeters.
Six of these multi-center investigations included Chinese patient cohorts to secure localized safety and efficacy datasets. Regulators in China are still evaluating the drug for type 2 diabetes after approving it for weight management.
Novo Nordisk challenges this progress with its own oral formulation of semaglutide, often referenced as oral Wegovy, kpanews.co.kr reported. The Danish drugmaker is actively pursuing regulatory clearance for the pill in China. While Novo Nordisk secured the initial U.S. launch for its oral semaglutide option, Eli Lilly captured the first-to-market approval advantage in China.
The domestic South Korean landscape mirrors this international rivalry. Both corporations filed applications with the Ministry of Food and Safety to secure local product approvals for oral Wegovy and Foundayo, kpanews.co.kr reported. Korea Lilly is also organizing a domestic Phase III clinical trial to assess the safety and efficacy of orforglipron specifically in overweight adult populations.
Current South Korean obesity care relies heavily on injectable GLP-1 options such as Wegovy and Mounjaro, kpanews.co.kr reported. Commercial success will depend on regulatory timelines, manufacturing supply volumes, pricing structures, and local reimbursement policies.
- Pill-Based Delivery: Unlike existing injectables, these new treatments use daily oral tablets that do not require strict meal timing.
| Drug Candidate | Company | Mechanism | Key Trial Data |
|---|---|---|---|
| Orforglipron (Foundayo) | Eli Lilly | Oral small-molecule GLP-1 receptor agonist | Average 12.4 kg reduction at 72 weeks (ATTAIN-1) |
| Oral Semaglutide (Wegovy pill) | Novo Nordisk | Oral peptide GLP-1 receptor agonist | Regulatory reviews and filings underway in key Asian markets |
Those with a history of severe gastrointestinal disease, pancreatitis, or hypersensitivity to the active ingredients must undergo careful clinical evaluation.
- kpanews.co.kr: Coverage on oral obesity drug approvals and market competition involving Eli Lilly and Novo Nordisk.
- ClinicalTrials.gov: ATTAIN-1 global Phase III clinical trial documentation for orforglipron.
